In this segment of the weekly health-care show, analyst David Williamson explains why investors need to have Arena Pharmaceuticals (NASDAQ:ARNA) on their radar. Watch and find out how a big EU approval decision, DEA scheduling, and the first quarter sales report of competitor Vivus's (NASDAQ:VVUS) Qsymia could impact the stock in the coming weeks.